Tuesday, December 11, 2018
The more scientists have learned about the community of benign bacteria inside our bodies, known as the microbiome, the more effort they have put into recruiting it in the fight against disease. What’s more, scientists occasionally discover that treatments long thought to work completely independently of our native microbes also relieve symptoms by interacting with them. New IRP research into the most commonly used medication for type 2 diabetes has led to just such a revelation by demonstrating that its benefits stem in part from its ability to kill off a particular species of bacteria in the human digestive tract.
Tuesday, February 13, 2018
Researchers have a long history of fattening up mice to gain insight into the causes and consequences of weight gain in the human body. In one of the more recent studies of this kind, a team of IRP researchers found that that a high-fat diet consistently altered the collection of microbes residing in mice’s digestive tracts and that this diet-microbe combination might pre-dispose the mice – and, potentially, obese humans – to colon cancer by triggering certain changes in how genes behave.
Thursday, December 15, 2016
Yasmine Belkaid, chief of the Mucosal Immunology Section in the NIAID Laboratory of Parasitic Diseases, has won the Sanofi–Institut Pasteur 2016 International Mid-Career Award for “outstanding research in the life sciences…contributing to progress in global public health,” announced on December 13, 2016 in Paris.